C. Morris

AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study

Reinhard Dummer, Caroline Robert, Paul B. Chapman et al. · Journal of Clinical Oncology · 2008 · 132 citations

Medicine, Pharmacology, Pharmacotherapy +14

Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study

Gillian Ellison, Maria Orr, Karin Kemsley et al. · British Journal of Cancer · 2009 · 101 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Cyclooxygenase-2 expression in the Barrett's metaplasia–dysplasia–adenocarcinoma sequence

C. Morris · The American Journal of Gastroenterology · 2001 · 88 citations

Medicine, Oncology, Pathology +16

O6-Methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma

MR Middleton, JM Lunn, C. Morris et al. · British Journal of Cancer · 1998 · 86 citations · Full text

Medicine, Molecular Biology, Oncology +14

Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours

David S. Boss, Gary K. Schwartz, Mark R. Middleton et al. · Annals of Oncology · 2009 · 63 citations

Medicine, Pharmacokinetics, Pharmacology +14